Streetbeat News

Products Services

21SHARES

CBOE

SOL

VANECK

Brazil has approved its second Solana ETF, while the U.S. faces regulatory hurdles for similar products. The SEC rejected proposals for Solana ETFs by VanEck and 21Shares, citing concerns over Solana's status as a security. Analysts suggest approval is unlikely without a change in U.S. regulatory leadership.

Portfolio Pulse from Aniket Verma

August 21, 2024 | 6:17 am

TSLA

Tesla has set a new production record at its Nevada Gigafactory, manufacturing over 500 Powerwalls in a single shift. This milestone is part of Tesla's strategy to ramp up energy storage deployments, with the company expecting significant growth in its energy business, outpacing its automotive segment.

Portfolio Pulse from Anan Ashraf

August 21, 2024 | 5:49 am

BONEUSD

SHIBUSD

Shiba Inu's lead developer, Shytoshi Kusama, highlighted the importance of the Bone ShibaSwap (BONE) token, emphasizing its integration into the project's governance and technology. BONE is crucial for ShibaSwap's decentralized exchange and Shibarium's transaction fees.

Portfolio Pulse from Aniket Verma

August 21, 2024 | 3:26 am

BABA

LUNR

PYPL

TGT

TSLA

On Tuesday, major U.S. indices fell, with notable stock movements including Alibaba's 3.42% drop due to unchanged Chinese interest rates, Intuitive Machines' 33.41% surge post-earnings, PayPal's 3.54% rise on positive analyst coverage, Target's slight 0.20% decline ahead of earnings, and Tesla's 0.73% drop amid concerns over market segment absence.

Portfolio Pulse from Benzinga Neuro

August 21, 2024 | 1:54 am

REGN

Regeneron Pharmaceuticals faced a setback as the FDA rejected its application for linvoseltamab, a blood cancer treatment, due to issues with a third-party manufacturer. Despite this, Regeneron's recent earnings were strong, with significant revenue growth.

Portfolio Pulse from Benzinga Neuro

August 21, 2024 | 1:26 am

TNXP

Tonix Pharmaceuticals (NASDAQ:TNXP) shares fell 14.61% after a 60% gain, following Q2 results showing a larger-than-expected loss. The company initiated a Phase 2 trial for TNX-1300, a treatment for acute cocaine intoxication, and highlighted progress on its TNX-801 vaccine for mpox and smallpox.

Portfolio Pulse from Henry Khederian

August 20, 2024 | 10:36 pm

EYEN

Eyenovia plans to offer and sell shares of its common stock or pre-funded warrants. The proceeds will be used for commercialization, clinical studies, and general corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 9:12 pm

AADI

Aadi Bioscience announced that its PRECISION1 trial is unlikely to meet the regulatory threshold for accelerated approval and will be halted. The trial's Independent Data Monitoring Committee found it unlikely to exceed the necessary efficacy threshold. Patients benefiting from nab-sirolimus can transition to an expanded access protocol.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 9:03 pm

NEXT

NextDecade's subsidiary has withdrawn its application at the Federal Energy Regulatory Commission (FERC) for a proposed carbon capture and storage project at the Rio Grande LNG facility.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 9:01 pm

OMCL

Omnicell, Inc. has launched Central Med Automation Service, a subscription-based solution aimed at optimizing centralized medication management for health systems. This service is expected to improve inventory visibility, scalability, and patient safety.

Portfolio Pulse from Benzinga Newsdesk

August 20, 2024 | 8:39 pm